Onkologische Welt, Table of Contents Onkologische Welt 2011; 02(06): 291-292DOI: 10.1055/s-0038-1632133 Kongressnachlese multidisziplinär Schattauer GmbH Metastasiertes Kolonkarzinom: Stetiger Anstieg der Lebenserwartung in den vergangenen 10 Jahren Peter Henning Dr. Recommend Article Abstract Buy Article Das Gesamtüberleben von Patienten mit mCRC ist in der vergangenen Dekade von 12,6–17,4 Monaten im Jahr 2000 auf 22,8-23,9 Monate im Jahr 2011 gestiegen und hat sich somit sukzessive verdoppelt, erläuterte Prof. Jean-Yves Douillard, Saint-Herblain, Frankreich. Full Text References Literatur 1 Douillard JY. et al. Final results from PRIME: Randomized phase III study of panitumumab (pmab) with FOLFOX4 for first line metastatic colorectal cancer (mCRC). ASCO Meeting Abstracts.. J Clin Oncol 2011; 29: 3510. 2 Douillard JY. et al. Safety of panitumumab (pmab) in combination with chemotherapy (ct) from five clinical trials in 812 patients (pts) with metastatic colorectal cancer (mCRC) and wild-type (WT) KRAS tumors. ASCO-GI 2010; Abstract Nr. 409. 3 Peeters M. et al. Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer.. J Clin Oncol 2010; 28: 4706-4713 DOI:10.1200/JCO.2009.27.6055. 4 Price TJ. et al. Randomized, open-label, phase III study of panitumumab (pmab) with FOLFIRI versus FOLFIRI alone as second-line treatment (tx) in patients (pts) with metastatic colorectal cancer (mCRC): Efficacy by skin toxicity (ST). ASCO Meeting Abstracts.. J Clin Oncol 2010; 28 (Suppl. 15) 3529. 5 Peeters M. et al. Evaluation of panitumumab (pmab) plus fluorouracil, leucovorin, and irinotecan (FOLFIRI) after first-line bevacizumab (bev) in patients (pts) with metastatic colorectal cancer (mCRC): A subgroup analysis of study 181. ASCO Meeting Abstracts.. J Clin Oncol 2011; 29: 3574. 6 Price TJ. et al. Efficacy of panitumumab plus FOLFI-RI versus FOLFIRI alone in patients with wild-type (wt) KRas metastatic colorectal cancer (mCRC) treated with prior oxaliplatin or bevacizumab regimes: Results from 20050181. ECCO16-ES-MO36-ESTRO30 Abstracts Nr. 6132.. EJC 2011; 47 (Suppl. 01) S431-S432. 7 Seymour MT. et al. Addition of panitumumab to irinotecan: Results of PICCOLO, a randomized controlled trial in advanced colorectal cancer (aCRC). Journal of Clinical Oncology, 2011 ASCO Annual Meeting Proceedings (Post-Meeting Edition 29 (15) suppl (May 20 Supplement 2011; 3523.
